The
p53 gene is justly famous for its role as a tumor suppressor. Loss of its
function through structural alterations (inactivating mutations, deletions)
occurs in roughly half of all humancancers, making it the most frequently
mutated cancer-associated gene [1]. Yet p53
does not function only to suppress cancer, as p53 homologues are present in
short-lived invertebrates such as worms (Caenorhabditis elegans)
and flies (Drosophila melanogaster) that do not develop cancer [2]. p53 is
known as the "guardian of the genome" and plays an important role in
maintaining genomic integrity in response to cellular damage and stress [3]. In
response to DNA damage, p53 is activated and can induce cell cycle arrest of
actively dividing cells, allowing time for repair of damage before re-entry
into the cell cycle. In other cases, where damage is extensive, p53 can induce
apoptosis, preventing the propagation of damaged or dysfunctional cells. It is
likely that p53 protects flies and worms primarily by regulating apoptosis
during embryogenesis. Yet p53 may play another role in flies as a longevity
regulator, as illustrated by a paper by Helfand and colleagues in this issue [4].How does the capacity of p53 to regulate
genomic integrity relate to its potential ability to regulate aging and
longevity? The first hints were obtained from genetically engineered mouse
models that exhibited accelerated aging phenotypes and shortened longevity [5,6]. Such
models frequently displayed evidence of an elevated p53 response, suggesting
that enhanced p53 activity might be partially responsible for these premature
aging phenotypes. More direct evidence for p53 involvement in longevity came
from studies on two mouse models that expressed truncated mutant forms of p53 [7,8]. These
mouse mutants, one generated by my laboratory,
were resistant to cancer, yet had significantlyshortened
longevity accompanied by a number of premature aging phenotypes. We
hypothesized that the truncated versions of p53 were causing aberrant
regulation of resident wildtype p53, resulting in an augmented p53-mediated
anti-proliferative response [9]. This
enhanced p53 response may inhibit functionality of stem and progenitor cell
compartments, leading to some of the tissue atrophies and dysfunctions that
accompanied the premature aging and shortened longevity phenotypes. A number
of laboratories have shown that increased activity of tumor suppressors such as
p53 and p16INK4a in stem cell compartments can lead to reduced stem
cell self renewal, tissue reconstitution function, and early tissue atrophies [10-14]. It
should be noted that transgenic mice with one or two copies of normally
regulated p53, while showing cancer resistance, did not have altered longevity [15]. However,
if an additional copy of the intact tumor suppressor p19ARF (which
activates p53) was co-expressed along with an additional copy of p53, aging
could actually be delayed [16]. Thus,
normally regulated, though augmented p53 function may be longevity enhancing,
while aberrantly regulated, but enhanced p53 activity is detrimental to
longevity (though both conditions inhibit cancer formation).The
clear influence of p53 on mouse longevity, either lengthening or shortening it,
led Helfand and colleagues to investigate the role of the Drosophilap53
homologue, Dmp53, in longevity [17]. They
found that null Dmp53 flies, while viable, are sickly and have a reduced
lifespan, probably due to early negative effects on embryonic development.
However, when two dominant negative mutants of p53 (shown to significantly
inhibit wildtype p53 transactivation activity) were expressed in the neuronal
cells of Drosophila, longevity was increased by up to 58%. Even if the
dominant negative (DN) p53 was expressed only in adult neurons, longevity
extension of 26% could be achieved. That this longevity effect was
tissue-specific was shown by the fact that DN Dmp53 expression in muscle or fat
body cells resulted in no longevity enhancement. Thus, DN dmp53 mediated
reduction of p53 activity in specific tissues could lead to delayed aging and
extended longevity.Insights
into the mechanisms of this neuronal Dmp53 effect were provided by the finding
that calorie restriction (CR) of the neuronal DN Dmp53 flies does not provide
any additional lifespan extension beyond that observed in non-restricted DN
Dmp53 flies [17]. Calorie
restriction is a consistent extender of longevity in worms, flies and mice. The
non-additive effects of DN p53 and CR argue that p53 signaling and calorie restriction
are operating in the same pathway or affecting the same pathway. In worms and
flies, the pathway most consistently associated with longevity effects has been
the insulin signaling pathway [18]. C.
elegans and Drosophila mutations in insulin signaling pathway
members that result in reduced insulin signaling often increase longevity and
enhance stress resistance, probably in part through enhanced dFoxO activity [19]. The
effects of calorie restriction phenocopy those observed in insulin signaling
mutants, and in flies the affected pathways may overlap. An important advance
by the Helfand laboratory was the recent demonstration that specific expression
of the DN Dmp53 transgene in the 14 neurons of the brain that produce
insulin-like peptides extends lifespan to a similar extent as pan-neuronal
expression [20]. The
primary effect of DN Dmp53 in the insulin-producing neurons was on reducing
production of insulin-like peptide 2 (dILP2), while other dILPs remained unaffected.
It was demonstrated that reduction of dILP2 production was sufficient to
inhibit downstream insulin signaling, as evidenced by reduced PI-3 kinase
function in fat bodies of both larval and adult flies. Moreover, increased
dFoxO nuclear accumulation was observed in fat body cells, a key downstream
readout for attenuated insulin signaling, as increased nuclear FoxO is
associated with increased stress resistance [19]. Thus,
alterations in p53 signaling in a specific subset of secretory neurons were
shown to cause major effects on insulin signaling pathways in critical target
organs such as the fat body.The most recent extension of the Helfand
laboratory findings are described in this issue [4]. Here,
they used an inducible GeneSwitch System to temporally manipulate expression of
the DN Dmp53 transgene. Turning on expression of the DN Dmp53 construct at 10
and 20 days of age in adult Drosophila brains led to 29% and 12% longer life
spans, respectively, compared to control flies. While less than the 47%
longevity extension observed in flies with constitutive lifelong DN Dmp53
expression, it demonstrates that the transgene longevity extension is not
solely due to positive embryonic or early life effects. The reverse experiment
of turning off DN Dmp53 expression also reduced lifespan extension
proportionate to the age of turnoff.The
earlier interactions of calorie restriction and DN Dmp53 longevity effects were
further examined by testing interactions of DN Dmp53 and dSir2
overexpression. Overexpression of the histone deace-tylase Sir2 has been
associated with increased lifespan in yeast, worms, and flies [21]. Moreover,
it is generally believed that CR acts in part through Sir2 activation, since
Sir2 overexpression and CR longevity extension effects are not additive in
flies [22]. Here,
the authors showed that Sir2 overexpressing DN Dmp53 flies showed the same
longevity as Sir2 overexpressing flies, indicating no additive effects of the
two alleles and that they were likely interacting in the same pathway relating
to CR. This result was confirmed by treament of control flies and DN Dmp53
flies with resveratrol, a molecular activator of Sir2 that has been shown to
extend lifespan in yeast, worms, and flies. No significant difference in fly
lifespan extension was observed among DN Dmp53 flies, resveratrol treated
control flies, and resveratrol treated DN Dmp53 flies, suggesting that CR,
dSir2 and DN Dmp53 act through similar pathways of longevity extension.The
pathway interactions of dSir2 and Dmp53 were confirmed at the biochemical level
by showing through co-immunoprecipitation experiments in fly head lysates that
Dmp53 and Sir2 physically interact with each other. In addition, purified recombinant
dSir2 protein deacetylated acetylated peptides corresponding to known sites of
Dmp53 acetylation in an NAD-dependent manner. Co-transfection of wildtype
Dmp53 with a p53 luciferase reporter in Drosophila cells in culture resulted in
transcriptional activation of the reporter that could be suppressed by adding
increasing doses of the Sir2 activator resveratrol. Thus, dSir2 was shown
directly to be a potent inhibitor of Dmp53 activity.The
experiments described above have facilitated the generation of a mechanistic
model for how calorie restriction activates downstream pathways important in Drosophila longevity extension. The Helfand laboratory has postulated that calorie
restriction acts in part through activation of dSir2 that in turn suppresses
Dmp53 in the insulin-producing cells of the brain [20]. Dmp53
suppression results in reduced production of at least one critical insulin-like
peptide (dILP2) by the insulin-producing cells. The reduced dILP production
may regulate a number of downstream targets in the insulin signaling pathway,
particularly in the fat body. Some of these targets, such as dFoxO, 4E-BP, and
TOR have been shown to play roles in lifespan control in model organisms.The key contribution of the series of Drosophilap53 papers from the Helfand laboratory is the placement of p53 as a key
mediator of downstream CR signaling effects, in part through its effects on
insulin signaling pathways. If confirmed by further studies, it will solidify a
role for p53 as a longevity regulating gene. As always, exciting results such
as these raise a number of new questions that beg to be addressed. For
example, how does Dmp53 regulate dILP2 expression to effect downstream insulin signaling pathway effects? Are the DN
Dmp53 effects solely through Dmp53 or are there other interaction targets?
Which of the downstream insulin signaling pathway targets mediate the lifespan
extension effects of activated dSir2 and suppressed Dmp53? The authors allude
to CR effects that are dSir2 and Dmp53 independent. What are these and are
they also insulin signaling independent? Does this model have applicability
to mammalian systems? In mice, where the effects of Sir2 homologues on
longevity are less clear and where adult tissue stem cells are believed to be
an important component of aging, different pathways or cell types may be
associated with CR-induced longevity effects. Unraveling these pathways in
various model systems should provide profound new insights into the genetics
and biology of aging and longevity.
Authors: Bernhard Maier; Wendy Gluba; Brian Bernier; Terry Turner; Khalid Mohammad; Theresa Guise; Ann Sutherland; Michael Thorner; Heidi Scrable Journal: Genes Dev Date: 2004-02-01 Impact factor: 11.361
Authors: Stuart D Tyner; Sundaresan Venkatachalam; Jene Choi; Stephen Jones; Nader Ghebranious; Herbert Igelmann; Xiongbin Lu; Gabrielle Soron; Benjamin Cooper; Cory Brayton; Sang Hee Park; Timothy Thompson; Gerard Karsenty; Allan Bradley; Lawrence A Donehower Journal: Nature Date: 2002-01-03 Impact factor: 49.962
Authors: Isabel García-Cao; Marta García-Cao; Juan Martín-Caballero; Luis M Criado; Peter Klatt; Juana M Flores; Jean-Claude Weill; María A Blasco; Manuel Serrano Journal: EMBO J Date: 2002-11-15 Impact factor: 11.598
Authors: Johannes H Bauer; Siti Nur Sarah Morris; Chengyi Chang; Thomas Flatt; Jason G Wood; Stephen L Helfand Journal: Aging (Albany NY) Date: 2009-01 Impact factor: 5.682
Authors: Johannes Bauer; Michael Antosh; Chengyi Chang; Christoph Schorl; Santharam Kolli; Nicola Neretti; Stephen L Helfand Journal: Aging (Albany NY) Date: 2010-05 Impact factor: 5.682
Authors: Mikhail V Blagosklonny; Judy Campisi; David A Sinclair; Andrzej Bartke; Maria A Blasco; William M Bonner; Vilhelm A Bohr; Robert M Brosh; Anne Brunet; Ronald A Depinho; Lawrence A Donehower; Caleb E Finch; Toren Finkel; Myriam Gorospe; Andrei V Gudkov; Michael N Hall; Siegfried Hekimi; Stephen L Helfand; Jan Karlseder; Cynthia Kenyon; Guido Kroemer; Valter Longo; Andre Nussenzweig; Heinz D Osiewacz; Daniel S Peeper; Thomas A Rando; K Lenhard Rudolph; Paolo Sassone-Corsi; Manuel Serrano; Norman E Sharpless; Vladimir P Skulachev; Jonathan L Tilly; John Tower; Eric Verdin; Jan Vijg Journal: Aging (Albany NY) Date: 2010-03-23 Impact factor: 5.682
Authors: Victoria L Haley; David J Barnes; Ionel Sandovici; Miguel Constancia; Christopher F Graham; Francesco Pezzella; Claudia Bühnemann; Emma J Carter; A Bassim Hassan Journal: EMBO Mol Med Date: 2012-06-06 Impact factor: 12.137
Authors: Lioubov G Korotchkina; Olga V Leontieva; Elena I Bukreeva; Zoya N Demidenko; Andrei V Gudkov; Mikhail V Blagosklonny Journal: Aging (Albany NY) Date: 2010-06 Impact factor: 5.682
Authors: Kimberley L Kaufman; Yiping Jenkins; Munther Alomari; Mehdi Mirzaei; O Giles Best; Dana Pascovici; Swetlana Mactier; Stephen P Mulligan; Paul A Haynes; Richard I Christopherson Journal: Oncotarget Date: 2015-12-01